A review of endocannabinoid system research reveals that peripheral CB1 receptors in fat tissue, liver, and muscle regulate metabolism independently of brain effects, opening new treatment possibilities after rimonabant's withdrawal.
Readers interested in how cannabis and the endocannabinoid system relate to weight and metabolism.
Peripherally restricted CB1 blockers improved metabolism in animals without psychiatric side effects
What the researchers found
This review charted the evolution of understanding about the endocannabinoid system (ECS) and metabolism. Early research focused on the brain: CB1 receptors in the hypothalamus and reward circuits drove food intake and energy balance. This led to rimonabant, a brain-penetrant CB1 antagonist that effectively treated obesity and metabolic disorders but was withdrawn in 2009 due to psychiatric side effects (depression, anxiety, suicidal ideation).
However, research has since revealed extensive peripheral ECS involvement in metabolism. CB1 receptors in adipose tissue, liver, skeletal muscle, and pancreas regulate fat storage, insulin sensitivity, lipid metabolism, and glucose homeostasis independently of brain effects. Peripherally restricted CB1 antagonists that cannot cross the blood-brain barrier have shown effectiveness in reducing body weight, adiposity, insulin resistance, and dyslipidemia in obese animal models, without the psychiatric side effects.
New developments include the discovery of endogenous allosteric inhibitors of CB1, the crystal structure of human CB1, and evidence that CB2 receptors also participate in metabolic regulation.
Why it matters
The withdrawal of rimonabant was a major setback for cannabinoid-based metabolic therapy. This review shows that the science did not stop there: peripheral ECS modulation may achieve the metabolic benefits of rimonabant without the psychiatric risks. Understanding how the endocannabinoid system regulates metabolism also explains aspects of the "munchies" and why chronic cannabis users have paradoxically been associated with lower obesity rates in some studies.
The numbers in context
Rimonabant was removed from the market in 2009. CB1 receptors are present in adipose tissue, liver, skeletal muscle, and pancreas. Peripherally restricted CB1 antagonists reduced body weight and metabolic markers in obese animals without CNS side effects.
How the study worked
Comprehensive narrative review covering the history, current state, and future directions of endocannabinoid system involvement in metabolic regulation.
What this study cannot tell us
Narrative review with potential for selective citation. Peripherally restricted CB1 antagonists have only been tested in animals at the time of this review. The complexity of the ECS makes predicting clinical outcomes from preclinical data particularly challenging. The full consequences of chronically blocking peripheral CB1 receptors are unknown.
How to read the evidence
Strong evidence from a comprehensive review synthesizing decades of preclinical and clinical metabolic research.
When this study was published
Published in 2017. Peripheral ECS modulation for metabolic disease remains an active area of drug development.
The bigger picture
The relationship between cannabis, the endocannabinoid system, and metabolism is more nuanced than "THC gives you the munchies." The ECS is a fundamental regulator of energy balance throughout the body, and its modulation offers therapeutic potential for obesity, diabetes, and metabolic syndrome. The challenge is harnessing these benefits without disrupting brain endocannabinoid signaling.
Questions still open
- Will peripherally restricted CB1 antagonists prove safe and effective in humans? How does chronic cannabis use affect peripheral metabolic ECS signaling? Could understanding the ECS explain the paradox of lower obesity in some cannabis-using populations?
Common questions
Why does cannabis give you the munchies?
If blocking CB1 receptors causes depression, how can it be used for weight loss?
Read the original research
MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
European journal of endocrinology, 176(6), R309-R324
Citation
Simon, Vincent; Cota, Daniela. (2017). MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.. European journal of endocrinology, 176(6), R309-R324. https://doi.org/10.1530/EJE-16-1044
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)